Skip to content

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.03B-78.2%
Incyte logo
IncyteINCY
$4.26M-4.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$166.77B+17.4%
Enterprise value$181.31B+12.0%
P/E18.1×-4.4×
P/S5.6×+0.7×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's current debt?
Gilead Sciences (GILD) reported current debt of $1.31B in Q1 2026.
How has Gilead Sciences's current debt changed year-over-year?
Gilead Sciences's current debt decreased by 53.2% year-over-year, from $2.81B to $1.31B.
What is the long-term trend for Gilead Sciences's current debt?
Over 5 years (2020 to 2025), Gilead Sciences's current debt has grown at a 0.4% compound annual growth rate (CAGR), from $2.76B to $2.81B.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.